StockData
Sagimet Biosciences Inc. logo

Sagimet Biosciences Inc. (SGMT) stock

SGMTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$9.85−0.28 (-2.76%)

Close on Nov 17, 2026Market cap $612.26MP/E –Yield –

Sagimet Biosciences operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Sagimet Biosciences's operating cash flow for the twelve months ending Jun 30, 2026 was -$41.72M. For fiscal 2025 it was -$45.65M.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$45.65M–
FY2024Dec 31, 2024-$42.44M–
FY2023Dec 31, 2023-$23.77M–
FY2022Dec 31, 2022-$24.49M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$11.10M–
Q1 FY2026Mar 31, 2026-$8.61M–
Q4 FY2025Dec 31, 2025-$11.83M–
Q3 FY2025Sep 30, 2025-$10.18M–
Q2 FY2025Jun 30, 2025-$9.10M–
Q1 FY2025Mar 31, 2025-$14.54M–
Q4 FY2024Dec 31, 2024-$11.02M–
Q3 FY2024Sep 30, 2024-$19.57M–
Q2 FY2024Jun 30, 2024-$5.63M–
Q1 FY2024Mar 31, 2024-$6.21M–
Q4 FY2023Dec 31, 2023-$7.08M–
Q3 FY2023Sep 30, 2023-$3.88M–
Q2 FY2023Jun 30, 2023-$5.72M–
Q1 FY2023Mar 31, 2023-$7.08M–
Q4 FY2022Dec 31, 2022-$7.45M–
Q3 FY2022Sep 30, 2022-$6.23M–
Q2 FY2022Jun 30, 2022-$3.00K–
Q1 FY2022Mar 31, 2022-$10.80M–

More Sagimet Biosciences figures

See a number that looks wrong?